<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927378</url>
  </required_header>
  <id_info>
    <org_study_id>2018[224]</org_study_id>
    <nct_id>NCT03927378</nct_id>
  </id_info>
  <brief_title>Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression</brief_title>
  <official_title>Effects of Low-dose S-Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression: A Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum depression is common in mothers early after childbirth and produces harmful
      effects not only on mothers, but also on infants and young children. Parturients with
      prenatal depression are at increased risk of postpartum depression. Low-dose s-ketamine can
      be used for antidepressant therapy. We hypothesize that low-dose s-ketamine has a therapeutic
      effect on parturients with prenatal depression. This study is designed to investigate whether
      low-dose s-ketamine administered after childbirth can reduce the incidence of postpartum
      depression in parturients with prenatal depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum depression refers to maternal depression developed early after childbirth, with
      reported incidences varied from 10% to 20%. The development of postpartum depression produces
      harmful effects not only on mothers, but also on infants and young children. Prenatal
      depression or high depression score is an independent risk factor for the development of
      postpartum depression.

      Ketamine is a commonly used general anesthetic. In addition, low-dose ketamine is recommended
      for antidepressant therapy. S-ketamine is more potent as an anaesthetic and might also have a
      better antidepressive effect. We hypothesize that low-dose s-ketamine has a therapeutic
      effect on parturients with prenatal depression. However, evidences in this aspect are
      insufficient. The purpose of this study is to investigate whether low-dose s-ketamine
      administered after childbirth can reduce the incidence of postpartum depression in
      parturients with prenatal depression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of depression at 42 days after childbirth.</measure>
    <time_frame>At 42 days after childbirth.</time_frame>
    <description>Postpartum depression at 42 days is diagnosed by using the Mini-International Neuropsychiatric Interview-Version 6.0 (MINI-V6.0) by a psychiatrist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The score of depression at 7 and 42 days after childbirth.</measure>
    <time_frame>At 7 and 42 days after childbirth.</time_frame>
    <description>The score of depression at 7 and 42 days after childbirth is assessed by using the Edinburgh Postpartum Depression Scale (EPDS). This is a 10-item self-report questionnaire; each item is rated from 0 to 3 denoting the increasing severity of symptoms, resulting in a total score range from 0 to 30, with higher score indicating more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The score of pain at 1, 7 and 42 days after childbirth.</measure>
    <time_frame>At 1, 7 and 42 days after childbirth.</time_frame>
    <description>The score of pain at 1, 7 and 42 days after childbirth is assessed by using a Numeric Rating Scale (an 11-point scale where 0 indicates no pain and 10 the worst pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of neonates with breast-feeding.</measure>
    <time_frame>At 1, 7 and 42 days after childbirth.</time_frame>
    <description>The proportion of neonates with breast-feeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of postpartum complications within 42 days after childbirth.</measure>
    <time_frame>Up to 42 days after childbirth.</time_frame>
    <description>The incidence of postpartum complications within 42 days after childbirth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of neonatal disease within 42 days after birth.</measure>
    <time_frame>Up to 42 days after childbirth.</time_frame>
    <description>The incidence of neonatal disease within 42 days after birth.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">364</enrollment>
  <condition>Perinatal Depression</condition>
  <condition>Ketamine</condition>
  <condition>Postpartum Depression</condition>
  <arm_group>
    <arm_group_label>S-katamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose s-ketamine (0.2 mg/kg in 20 ml normal saline) is intravenously infused in 40 minutes after childbirth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (20 ml normal saline) is intravenously infused in 40 minutes after childbirth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-ketamine</intervention_name>
    <description>S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.</description>
    <arm_group_label>S-katamine group</arm_group_label>
    <other_name>S-ketamine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parturients with age ≥18 years;

          -  Presence of prenatal depression (EPDS score ≥10);

          -  Provide written informed consents.

        Exclusion Criteria:

          -  History of psychiatric disease (schizophrenia) or communication barriers that prevent
             normal communication before childbirth;

          -  Severe complications during pregnancy (such as severe preeclampsia, placenta accreta,
             or HELLP [Hemolysis, Elevated Liver enzymes and Low Platelets] syndrome);

          -  ASA physical status classification ≥III;

          -  Presence of contraindications to ketamine, including refractory hypertension, severe
             cardiovascular disease (heart function classification ≥III), or hyperthyroidism;

          -  Refuse to participate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <phone>8610 83572784</phone>
    <email>wangdongxin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Zeng, MD</last_name>
    <phone>8610 83572460</phone>
    <email>yuan_zeng@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Xin Wang, MD, PhD</last_name>
      <phone>861083572784</phone>
      <email>wangdongxin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuan Zeng, MD</last_name>
      <phone>861083572460</phone>
      <email>yuan_zeng@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Nonacs R, Cohen LS. Postpartum mood disorders: diagnosis and treatment guidelines. J Clin Psychiatry. 1998;59 Suppl 2:34-40. Review.</citation>
    <PMID>9559758</PMID>
  </reference>
  <reference>
    <citation>Kim S, Soeken TA, Cromer SJ, Martinez SR, Hardy LR, Strathearn L. Oxytocin and postpartum depression: delivering on what's known and what's not. Brain Res. 2014 Sep 11;1580:219-32. doi: 10.1016/j.brainres.2013.11.009. Epub 2013 Nov 14. Review.</citation>
    <PMID>24239932</PMID>
  </reference>
  <reference>
    <citation>Giallo R, Pilkington P, McDonald E, Gartland D, Woolhouse H, Brown S. Physical, sexual and social health factors associated with the trajectories of maternal depressive symptoms from pregnancy to 4 years postpartum. Soc Psychiatry Psychiatr Epidemiol. 2017 Jul;52(7):815-828. doi: 10.1007/s00127-017-1387-8. Epub 2017 Apr 27.</citation>
    <PMID>28451700</PMID>
  </reference>
  <reference>
    <citation>Giallo R, Cooklin A, Nicholson JM. Risk factors associated with trajectories of mothers' depressive symptoms across the early parenting period: an Australian population-based longitudinal study. Arch Womens Ment Health. 2014 Apr;17(2):115-25. doi: 10.1007/s00737-014-0411-1. Epub 2014 Jan 15.</citation>
    <PMID>24424796</PMID>
  </reference>
  <reference>
    <citation>Sutter-Dallay AL, Cosnefroy O, Glatigny-Dallay E, Verdoux H, Rascle N. Evolution of perinatal depressive symptoms from pregnancy to two years postpartum in a low-risk sample: the MATQUID cohort. J Affect Disord. 2012 Jun;139(1):23-9. doi: 10.1016/j.jad.2011.08.018. Epub 2012 Mar 11.</citation>
    <PMID>22410506</PMID>
  </reference>
  <reference>
    <citation>McCall-Hosenfeld JS, Phiri K, Schaefer E, Zhu J, Kjerulff K. Trajectories of Depressive Symptoms Throughout the Peri- and Postpartum Period: Results from the First Baby Study. J Womens Health (Larchmt). 2016 Nov;25(11):1112-1121. Epub 2016 Jun 16.</citation>
    <PMID>27310295</PMID>
  </reference>
  <reference>
    <citation>Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception. 2010 Aug;82(2):174-7. doi: 10.1016/j.contraception.2010.03.004. Epub 2010 Apr 13.</citation>
    <PMID>20654759</PMID>
  </reference>
  <reference>
    <citation>Ding T, Wang DX, Qu Y, Chen Q, Zhu SN. Epidural labor analgesia is associated with a decreased risk of postpartum depression: a prospective cohort study. Anesth Analg. 2014 Aug;119(2):383-92. doi: 10.1213/ANE.0000000000000107.</citation>
    <PMID>24797120</PMID>
  </reference>
  <reference>
    <citation>Quevedo LA, Silva RA, Godoy R, Jansen K, Matos MB, Tavares Pinheiro KA, Pinheiro RT. The impact of maternal post-partum depression on the language development of children at 12 months. Child Care Health Dev. 2012 May;38(3):420-4. doi: 10.1111/j.1365-2214.2011.01251.x. Epub 2011 Jun 8.</citation>
    <PMID>21651606</PMID>
  </reference>
  <reference>
    <citation>Parsons CE, Young KS, Rochat TJ, Kringelbach ML, Stein A. Postnatal depression and its effects on child development: a review of evidence from low- and middle-income countries. Br Med Bull. 2012;101:57-79. doi: 10.1093/bmb/ldr047. Epub 2011 Nov 29. Review.</citation>
    <PMID>22130907</PMID>
  </reference>
  <reference>
    <citation>Weitzman M, Rosenthal DG, Liu YH. Paternal depressive symptoms and child behavioral or emotional problems in the United States. Pediatrics. 2011 Dec;128(6):1126-34. doi: 10.1542/peds.2010-3034. Epub 2011 Nov 7.</citation>
    <PMID>22065273</PMID>
  </reference>
  <reference>
    <citation>Demontigny F, Girard ME, Lacharité C, Dubeau D, Devault A. Psychosocial factors associated with paternal postnatal depression. J Affect Disord. 2013 Aug 15;150(1):44-9. doi: 10.1016/j.jad.2013.01.048. Epub 2013 Mar 13.</citation>
    <PMID>23489392</PMID>
  </reference>
  <reference>
    <citation>Dietz LJ, Jennings KD, Kelley SA, Marshal M. Maternal depression, paternal psychopathology, and toddlers' behavior problems. J Clin Child Adolesc Psychol. 2009 Jan;38(1):48-61. doi: 10.1080/15374410802575362.</citation>
    <PMID>19130357</PMID>
  </reference>
  <reference>
    <citation>Pawlby S, Sharp D, Hay D, O'Keane V. Postnatal depression and child outcome at 11 years: the importance of accurate diagnosis. J Affect Disord. 2008 Apr;107(1-3):241-5. Epub 2007 Sep 12.</citation>
    <PMID>17854906</PMID>
  </reference>
  <reference>
    <citation>Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004 Jul-Aug;26(4):289-95. Review.</citation>
    <PMID>15234824</PMID>
  </reference>
  <reference>
    <citation>Klainin P, Arthur DG. Postpartum depression in Asian cultures: a literature review. Int J Nurs Stud. 2009 Oct;46(10):1355-73. doi: 10.1016/j.ijnurstu.2009.02.012. Epub 2009 Mar 26. Review.</citation>
    <PMID>19327773</PMID>
  </reference>
  <reference>
    <citation>Eisenach JC, Pan PH, Smiley R, Lavand'homme P, Landau R, Houle TT. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain. 2008 Nov 15;140(1):87-94. doi: 10.1016/j.pain.2008.07.011. Epub 2008 Sep 24.</citation>
    <PMID>18818022</PMID>
  </reference>
  <reference>
    <citation>Lee DT, Yip AS, Leung TY, Chung TK. Identifying women at risk of postnatal depression: prospective longitudinal study. Hong Kong Med J. 2000 Dec;6(4):349-54.</citation>
    <PMID>11177155</PMID>
  </reference>
  <reference>
    <citation>Jardri R, Pelta J, Maron M, Thomas P, Delion P, Codaccioni X, Goudemand M. Predictive validation study of the Edinburgh Postnatal Depression Scale in the first week after delivery and risk analysis for postnatal depression. J Affect Disord. 2006 Jul;93(1-3):169-76. Epub 2006 Apr 27.</citation>
    <PMID>16644021</PMID>
  </reference>
  <reference>
    <citation>Milgrom J, Gemmill AW, Bilszta JL, Hayes B, Barnett B, Brooks J, Ericksen J, Ellwood D, Buist A. Antenatal risk factors for postnatal depression: a large prospective study. J Affect Disord. 2008 May;108(1-2):147-57. Epub 2007 Dec 18.</citation>
    <PMID>18067974</PMID>
  </reference>
  <reference>
    <citation>Dennis CL. Can we identify mothers at risk for postpartum depression in the immediate postpartum period using the Edinburgh Postnatal Depression Scale? J Affect Disord. 2004 Feb;78(2):163-9.</citation>
    <PMID>14706728</PMID>
  </reference>
  <reference>
    <citation>Huynh NN, McIntyre RS. What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis. Prim Care Companion J Clin Psychiatry. 2008;10(2):91-6.</citation>
    <PMID>18458732</PMID>
  </reference>
  <reference>
    <citation>Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health. 2016 May;19(2):35-8. doi: 10.1136/eb-2016-102355. Epub 2016 Apr 6. Review.</citation>
    <PMID>27053196</PMID>
  </reference>
  <reference>
    <citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.</citation>
    <PMID>10686270</PMID>
  </reference>
  <reference>
    <citation>Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depress Anxiety. 2016 Aug;33(8):689-97. doi: 10.1002/da.22501. Epub 2016 Apr 6. Review.</citation>
    <PMID>27062302</PMID>
  </reference>
  <reference>
    <citation>Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015 Oct;172(10):950-66. doi: 10.1176/appi.ajp.2015.15040465. Review.</citation>
    <PMID>26423481</PMID>
  </reference>
  <reference>
    <citation>Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016 May;46(7):1459-72. doi: 10.1017/S0033291716000064. Epub 2016 Feb 12.</citation>
    <PMID>26867988</PMID>
  </reference>
  <reference>
    <citation>Drewniany E, Han J, Hancock C, Jones RL, Lim J, Nemat Gorgani N, Sperry JK 3rd, Yu HJ, Raffa RB. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. J Clin Pharm Ther. 2015 Apr;40(2):125-30. doi: 10.1111/jcpt.12238. Epub 2014 Dec 26.</citation>
    <PMID>25545040</PMID>
  </reference>
  <reference>
    <citation>Strasburger SE, Bhimani PM, Kaabe JH, Krysiak JT, Nanchanatt DL, Nguyen TN, Pough KA, Prince TA, Ramsey NS, Savsani KH, Scandlen L, Cavaretta MJ, Raffa RB. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther. 2017 Apr;42(2):147-154. doi: 10.1111/jcpt.12497. Epub 2017 Jan 22. Review.</citation>
    <PMID>28111761</PMID>
  </reference>
  <reference>
    <citation>Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20. Review.</citation>
    <PMID>25038867</PMID>
  </reference>
  <reference>
    <citation>Park M, Niciu MJ, Zarate CA Jr. Novel Glutamatergic Treatments for Severe Mood Disorders. Curr Behav Neurosci Rep. 2015 Dec;2(4):198-208. Epub 2015 Oct 9.</citation>
    <PMID>26824031</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Professor and Chairman, Department of Anesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Perinatal Depression</keyword>
  <keyword>S-Ketamine</keyword>
  <keyword>Postpartum Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

